Panobinostat (LBH589)

Catalog No.S1030 Synonyms: NVP-LBH589

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Size Price Stock Quantity  
USD 90 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 52 Publications

12 Customer Reviews

  • (G) A375 parental and BRAFi-resistant ex vivo clones were treated with a panel of HDACi (1 μM vorinostat, 0.5 μM belinostat, and 6 nM panobinostat) in single treatment or in combination with 1 μM vemurafenib in a long-term colony formation assay.

    Cell, 2018, 173(6):1413-1425. Panobinostat (LBH589) purchased from Selleck.

    LSD1 and HDAC inhibitors exhibit synergistic growth inhibition. Cells were simultaneously treated with pargyline or HDAC inhibitors for 48 h.

     

     

    Breast Cancer Res Treat 2012 131, 777-789. Panobinostat (LBH589) purchased from Selleck.

  • Using CRISPR-Cas9 technology, ERα was silenced at the genomic level in ECC1 cells. Ishikawa, parental ECC1 cells and individual ESR1 KO ECC1 clones were treated with 20 nM LBH589 for 24 hr. Expression of ERα, PR, FOXO1, and Myc were evaluated by Western blotting. β-actin serves as a loading control.

    PLoS One, 2016, 11(2):e0148912.. Panobinostat (LBH589) purchased from Selleck.

    HDACIs That Simultaneously Inhibit HDACs 1 and 6 Showed Greater Antileukemic Activities than HDACIs that Don’t at Cmax Concentrations. THP-1 cells were treated with LBH-589, PXD101, SAHA, VPA, MS-275 and MGCD0103 at Cmax concentrations for 3 h and 24 h, respectively. The cells post 3 h treatments were washed three times with complete medium and divided into two halves. One half of the cells was resuspended in complete media and cultured for up to 24 h to determine the effects of the 3 h treatments on cell proliferation and apoptosis. The other half of the cells was used to prepare whole cell lysates. Whole cell lysates from the 3 h and 24 h treatments were extracted and subjected to Western blots probed by anti-ac-tubulin or –b-actin antibody (panels A&B), or subjected to HDAC1 enzymatic assays post IP as described in the Materials and Methods (Panels C&D). The effects of the 3 h and 24 h HDACI treatments on cell proliferation, as reflected by percent decrease of live cells relative to untreated cells (panel E), and apoptosis (panel F) were determined by flow cytometry analysis as described in the Materials and Methods.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

  • Induction of DNA Damage and Bim Is Critical for HDACI-Induced Apoptosis in Pediatric AML Cells. THP-1 cells were treated with the HDACIs at Cmax concentrations for 3 (panel A) and 24 h (panel B), respectively. Whole cell lysates were extracted and subjected to Western blots probed by anti-p21, -c-Myc, -cH2AX, -Bim, or -b-actin antibody.

     

     

    PLoS One 2011 6, e17138. Panobinostat (LBH589) purchased from Selleck.

    Cell death induction by LBH589 as a single agent was detected in control or MTDH knockdown Hec50co cells. After 3 days, cell death was determined by the WST-1 method.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

  • Expression of pro-/anti-apoptosis genes. Control or MTDH knockdown Hec50co cells were treated for 24 hours with vehicle control, 20 nM LBH589, 25 ng/ml TRAIL or LBH589 and TRAIL at the concentrations noted. Lysates were collected. Expression of DR4, DR5, and apoptosis related caspase-3, caspase-8, PARP-1, BID, FLIP, XIAP, Bim, MCL-1 and BCL-XL was analyzed by Western blotting.

    PLoS One 2011 6, e20920. Panobinostat (LBH589) purchased from Selleck.

    p53(+/+) and (/) HCT116 cells were treated with TSA (1–5 lM),LBH589 (2–5 lM), valproate (2.5–5 mM), MS-275 (20 lM) and sodium butyrate (2 mM). TAp63 expression was compared in both cell lines after 24 h of treatment. Consistent with the above data, all HDAC inhibitors failed to induce significant levels of TAp63 in p53(/) HCT116 cells.

     

     

    Biochem Bioph Res Co 2009 391, 1748-1751. Panobinostat (LBH589) purchased from Selleck.

  • Effect of panobinostat on the viability of cervical cancer cells. HeLa (A) and SiHa (B) cells were treated with increasing concentrations of panobinostat for 24, 48 and 72 h. Cell viability was determined by MTT assay. The results are presented as percentage; calculated from the reduction in cell viability at a given concentration of drug compared to the untreated control (untreated control being 100%). The IC5072h values were calculated from sigmoidal dose-response curves generated in Prism 5.0 (GraphPad). (C) Cytotoxic effects of panobinostat on HeLa and SiHa cells measured at 72 h and expressed as% cell death. Each value is the mean ± SD of three independent experiments performed in triplicates.

    Biomed Pharmacother, 2016, 84:1393-1405. Panobinostat (LBH589) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-10μM Panobinostat was added.

    Dr.Zhang of Tianjin Medical University. Panobinostat (LBH589) purchased from Selleck.

  • HDAC inhibitors induce p63a expression (A) HCT116 cells were treated with TSA (1 lM), LBH589 (2 lM), valproate (2.5 mM), MS-275 (20 lM) and sodium butyrate(2 mM) for 24 h. Expression of p63 was assessed by Western blotting with the H129 pan-anti-p63 antibody. Although TSA and LBH589 induced p63 efficiently, valproate, MS-275 and sodium butyrate were much less efficient. The lower panel shows the actin loading control. Arrow indicates TAp63. (B) The HDAC inhibitors used in this study are shown, grouped according to their structure and with their HDAC specificity. The efficiency of TAp63 expression is shown in the last column.

     

     

    Dr. Berna S. Sayan of Leicester University. Panobinostat (LBH589) purchased from Selleck.

    U266 and KMS-11 were treated with 20 nM panobinostat for 48 h followed by Western blot analysis. Actin served as a loading control. Nine (U266) and 3 (KMS-11) biologically independent experiments were performed. To determine the expression of PPP3CA mRNA in treated cells for 24 h, we performed relative quantification real-time PCR (n = 6). Four (U266) and 2 (KMS-11) biologically independent experiments were performed.

    JCI Insight, 2016, 1(5):e85061. Panobinostat (LBH589) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Targets
HDAC (MOLT-4 cells) [1] HDAC (Reh cells) [1]
5 nM 20 nM
In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. [1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT29 NIX3TlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[3dI5oOC1zMDFOwG0> MkHwNE01KGR? M2ix[IlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWiyOlcxOjd6NB?=
HepG2 NVjIcmp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn7tNE0yOCEQvF2= MoqwNE01KGR? M2O3W4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUOyOlcxOjd6NB?=
HT29 NET6ZWVHfW6ldHnvckBCe3OjeR?= MYS1NOKhdk1? NYTvXFBtOjRvN{KgbC=> M1n0Nolv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=> NVuybWl{OjZ5MEK3PFQ>
HepG2 Mn\GSpVv[3Srb36gRZN{[Xl? MWC1NOKhdk1? NXT6bG1mOjRvN{KgbC=> MkHBbY5lfWOnZDDhZ5RqfmG2aX;uJI9nKGOjc4Dhd4UhOyCjZoTldkAzPMLiaNMg M3fySlI3PzB{N{i0
HCC827 NFrCXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPhOU84NjVxMUCgcm0> MXy3NuKhcA>? M1HrbWROW09? NWTQXXU5\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MUeyOlY4PTR6NB?=
A549  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWixNE8yPS9{MDDuUS=> MkDYO|LDqGh? MnLlSG1UVw>? NHrZTGRmdmijbnPld{B1cGViYX70bZBzd2yrZnXyZZRqfmViZX\m[YN1KG:oIHXycI91cW6rYh?= Mn3vNlY3PzV2OES=
NCI-H460  NHvMNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2Xye|ExNzJyL{OwJI5O MmPGO|LDqGh? NU\ZTG9STE2VTx?= NVv2XXM3\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK= MVKyOlY4PTR6NB?=
J89GFP NHrmZmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXiOGt5TE2VT9Mg NWHoU2NSTUN3ME20PU45PSEEsTCxNk43PSCwTR?= NFvnWXMzPjV4M{W2PC=>
THP89GFP MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3TeWFFVVORwrC= NHO5UI5GSzVyPUG5MlM1KMLzIE[uOFMhdk1? NYTUbG9pOjZ3NkO1Olg>
SK-NEP-1 Mn34S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX2wMlAy6oDVMUCuNEDPxE1? MkezNlQhcA>? NIHR[GdFVVORwrC= NXXHOZQ1UUN3ME23Ok4{PCCwTR?= NFP0PYczPjF5NkKxPS=>
G401 NGTRcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXVd|JCOC5yMfMAl|ExNjBizszN M{nXd|I1KGh? NYPPUnM3TE2VT9Mg Mlz0TWM2OD1zNEOuNFIhdk1? NXPPNVVROjZzN{[yNVk>
SK-NEP-1 NFnKTJpE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MV61NEBvVQ>? NH65Rmwy6oDVNDDk NX\F[4FZTE2VT9Mg NVvZSppremWmdXPld{Bk\WyuIIP1dpZqfmGuIHnuJIEhfGmvZTDk[ZBmdmSnboSgcYFvdmW{ NXi0enFKOjZzN{[yNVk>
G401 NH7yfJRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NXr6U4RxPTBibl2= NH3jO5oy6oDVNDDk NITxXJNFVVORwrC= NFfXU4xz\WS3Y3XzJINmdGxic4Xyeol3[WxiaX6gZUB1cW2nIHTldIVv\GWwdDDtZY5v\XJ? M1G0dlI3OTd4MkG5
SK-NEP-1 MonIRZBweHSxc3nzJGF{e2G7 NITyTXI2OC9zMECgcm0> Ml7lNlQhcA>? MoDHSG1UV8Li MnnnbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXGyOlE4PjJzOR?=
G401 NIXwNZNCeG:ydH;zbZMhSXO|YYm= MWK1NE8yODBibl2= MWKyOEBp MXrEUXNQyqB? MV\pcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NHnoNVQzPjF5NkKxPS=>
SK-NEP-1 MkLmSpVv[3Srb36gRZN{[Xl? NUXEUFAxPTBxMUCwJI5O NYHUd21HOjRiaB?= NHTZTHlFVVORwrC= M161OJNpd3e|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25? M4X5S|I3OTd4MkG5
G401 MULGeY5kfGmxbjDBd5NigQ>? Mkm3OVAwOTByIH7N M{\wU|I1KGh? NHXPcIdFVVORwrC= NGDhO|V{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w MX:yOlE4PjJzOR?=
SK-NEP-1 NYPqdIFOTnWwY4Tpc44hSXO|YYm= NVnMe|RDPTBxMUCwJI5O NWXBe5p2OjRiaB?= MkmxSG1UV8Li NUexbpo2cW6mdXPld{Bk\WyuIHP5Z4xmKGSrc3;y[IVzyqB? NWDZbFFjOjZzN{[yNVk>
G401 NW\LSZZYTnWwY4Tpc44hSXO|YYm= MYK1NE8yODBibl2= NX\D[ZlJOjRiaB?= M{\FTGROW00EoB?= MVHpcoR2[2W|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=> M4XH[|I3OTd4MkG5
RPMI 8226 MVPD[YxtKFO3co\peoFtKEG|c3H5 M1jnNlIwPC94IH7N NGWxdmo1QOLCiXi= NIToUXJqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MXWyOlAxODJ7Mh?=
OPM2 NF;zfW1E\WyuIGP1dpZqfmGuIFHzd4F6 NV;2UWEzOi92L{[gcm0> M133T|Q56oDLaB?= NXLUdnFucW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?= M4fURVI3ODByMkmy
U266 M4LwWmNmdGxiU4Xyeol3[WxiQYPzZZk> MWqyM|QwPiCwTR?= NGHESYE1QOLCiXi= M125TIlv\HWlZYOgZUB{cWewaX\pZ4FvfCCmZXPy[YF{\SCrbjD0bIUh[2WubDDndo94fGh? MmfTNlYxODB{OUK=
H929 NUnSc|hwS2WubDDTeZJ3cX[jbDDBd5NigQ>? MmPsNk81NzZibl2= MkjaOFjjiImq NG[yO4JqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq MUGyOlAxODJ7Mh?=
RPMI 8226  M1jFZWFxd3C2b4Ppd{BCe3OjeR?= NXW4NHVDPOLCiX7N NEnWUpczPC92ODDo NFPrWoZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ Mn;MNlYxODB{OUK=
HCC827 MknQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm\GNVAhdk1? NIro[4s1QCCq MXfEUXNQ NGjrZlBmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?= Mo\mNlU6PDR4MUe=
NCI-H23 M{HIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3WXnpVOTBibl2= M2XuNlQ5KGh? M3\kU2ROW09? NWjLemdb\W6qYX7j[ZMh[2m|cHzheIlvKHOnboPpeIl3cXS7wrC= MnLXNlU6PDR4MUe=
AML3 NEPaVWRHfW6ldHnvckBCe3OjeR?= NYraZmcxOC1zIN88US=> MmrHNlTDqGh? M2jF[Ilv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVOyOVYyOjl2MR?=
ML-1 MlXBSpVv[3Srb36gRZN{[Xl? M1LSblAuOSEQvF2= M2m0[|I1yqCq MofhbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4DYeFI2PjF{OUSx
RPMI-8226vr10  M2XKZWZ2dmO2aX;uJGF{e2G7 NV[3OIRbOC1zIN88US=> NVX4S45jOjUEoHi= MljmbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4\w[FI2PjF{OUSx
ML-1 MoiwSpVv[3Srb36gRZN{[Xl? MX[xJO69VQ>? MYSyOOKhcA>? NHm3V4VqdmO{ZXHz[ZMh[2G|cHHz[U0{KGGldHn2bZR6KDRvZn;s[C=> MXGyOVYyOjl2MR?=
RPMI-8226vr10  M4\1ZWZ2dmO2aX;uJGF{e2G7 M3LqSVEh|ryP M2PDUVI1yqCq M33iZ4lv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhOi53LX\vcIQ> MnS4NlU3OTJ7NEG=
SK-N-BE (2) Mk\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLuNlTjiImq MXfJR|UxRTFyND6w5qCKyrIkgJm3Mlghdk1? Mln1NlU{ODh7MU[=
SK-N-BE (2), PAN  MK MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUS3VZo5OjUkgJno NHHn[4NKSzVyPUGwOE4x6oDLwsJihKk4Njhibl2= MXSyOVMxQDlzNh?=
SK-N-BE (2), MK  PAN NEnHbldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\PWXEzPOLCiXi= MULJR|UxRTN6Mj6w5qCKyrIkgJm0N{4zKG6P MWSyOVMxQDlzNh?=
SK-N-AS MkT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVeyOQKBkWh? MXXJR|UxRTN5LkJihKnDueLCiUKuOEBvVQ>? NXfPbFhCOjV|MEi5NVY>
SK-N-DZ MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLWVJF[OjUkgJno M1XCR2lEPTB;MUeuNgKBkcLz4pEJNE41KG6P NIXISXIzPTNyOEmxOi=>
Caki-1 MoXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjNdGMyOC9{NT:1NEBvVQ>? NFzqNZg1QCCq M2fGe4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?= MXSyOVI4QTF7MR?=
ACHN MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlPyNVAwOjVxNUCgcm0> M3LrfVQ5KGh? NYXHc3B6cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny MlHHNlUzPzlzOUG=
769-P M3W1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fWflExNzJ3L{WwJI5O NEXPdGk1QCCq MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCC{aYTvcoF3cXJ? Ml7pNlUzPzlzOUG=
786-O  M2XDXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULISZRMOTBxMkWvOVAhdk1? NV\CUmpRPDhiaB?= NIjnZ5NqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK= NYfkbXA1OjV{N{mxPVE>
Caki-1 NFrTVGhCeG:ydH;zbZMhSXO|YYm= NWS2TWp3PTBibl2= NHXpNo41QCCq NYDMcGdVcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDjc41jcW6nZDDybZRwdmG4aYK= Mn64NlUzPzlzOUG=
ACHN MlvpRZBweHSxc3nzJGF{e2G7 M1;TelUxKG6P M1nwUFQ5KGh? Ml\mbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? M1nF[|I2Ojd7MUmx
769-P M{LGUGFxd3C2b4Ppd{BCe3OjeR?= NF\2c|M2OCCwTR?= NXXM[HNuPDhiaB?= MnfUbY5lfWOnczDj[YxtKGGyb4D0c5NqeyClb33ibY5m\CC{aYTvcoF3cXJ? Ml\XNlUzPzlzOUG=
786-O  M{Cxb2Fxd3C2b4Ppd{BCe3OjeR?= NFvmVW02OCCwTR?= MnrFOFghcA>? M{jDUYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{ NIK0WVUzPTJ5OUG5NS=>
Caki-1 M4WyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[yOU82OCCwTR?= MVS0PEBp NFj4VopFVVOR MoXjbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= NXzpV|MxOjVzN{[zOVQ>
ACHN NFP4[I1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGyOU82OCCwTR?= MnTkOFghcA>? MmXmSG1UVw>? MnOwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?= MXmyOVE4PjN3NB?=
769-P MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPydow5OjVxNUCgcm0> NXLTOXFnPDhiaB?= NIrpe2VFVVOR MXLpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk MlfPNlUyPzZ|NUS=
Caki-1 MWHDc4xwdnliRn;ycYF1cW:wIFHzd4F6 NHjTPYk2OCCwTR?= MXO3MVE1KGR? NUf5fXdQTE2VTx?= MnzUd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> NF7UcGYzPTF5NkO1OC=>
ACHN MYXDc4xwdnliRn;ycYF1cW:wIFHzd4F6 MWW1NEBvVQ>? MYm3MVE1KGR? MUnEUXNQ MU\zeZBxemW|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=> MYSyOVE4PjN3NB?=
769-P MoDRR49td267IF\vdo1ifGmxbjDBd5NigQ>? MlXjOVAhdk1? M2fPXFcuOTRiZB?= NHXPSHBFVVOR Ml;Cd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA> MXSyOVE4PjN3NB?=
Caki-1 NEfWNYJCeG:ydH;zbZMhSXO|YYm= MkfUOVAhdk1? M{n6XVQ5KGh? NWDqdGhHTE2VTx?= NUiwXosxcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NELFVHUzPTF5NkO1OC=>
ACHN MX3BdI9xfG:|aYOgRZN{[Xl? NFrvPWg2OCCwTR?= MlThOFghcA>? Mne3SG1UVw>? NEHSOpBqdmS3Y3XzJINmdGxiYYDvdJRwe2m| Moq2NlUyPzZ|NUS=
769-P NFHQNJlCeG:ydH;zbZMhSXO|YYm= M4LnTlUxKG6P MWm0PEBp NWHmRY5WTE2VTx?= NWDSeIdOcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWXVcGNkOjVzN{[zOVQ>
MDA-MB-231 MlG1UY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 MWmxNOKhdk1? MlztN:Kh\A>? NFW4eoJFVVOR MkLwZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NWnLTWlUOjR6MUC0PVc>
BT-549 MlHsUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6 M37TUFExyqCwTR?= MUizxsBl MXnEUXNQ MXzhcJRmenNiY3XscEBud3KyaH;sc4d6yqB? MnzmNlQ5OTB2OUe=
MCF-7  M3vRdm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>? NI\hTWoyOMLibl2= NHOwdng{yqCm MlrQSG1UVw>? MkLDZYx1\XK|IHPlcIwhdW:{cHjvcI9ogcLi NHnkfmszPDhzMES5Oy=>
MCF-7 NHH2NHVHfW6ldHnvckBCe3OjeR?= NIP1VWI2NTVyIH7N M4LjeVI1KGh? NEPyblJFVVOR MmnIdoVlfWOnZDD0bIUhdGW4ZXygc4Yh\XiycnXzd4lwdiCxZjDFVu6yNCCSUjDhcoQhTm:6QUJCpC=> NY\qbI1OOjR|Nk[0NFc>
CTS NFTiZoFCeG:ydH;zbZMhSXO|YYm= M{e5cVDjiJN2MDDuUeKh M2XGfFQ5KGh? NVizN4VXcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{fQN|I1OjR2NEK5
OCI-AML3  MoLYRZBweHSxc3nzJGF{e2G7 NHzVXG4x6oDVNECgcm3DqA>? MXG0PEBp MmTDbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MUKyOFI1PDR{OR?=
U937 NX;kdZhpSXCxcITvd4l{KEG|c3H5 M4jnUFDjiJN2MDDuUeKh NG\xUXY1QCCq MUXpcoR2[2W|IHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWfjb4d7OjR{NES0Nlk>
PC3 MVPBdI9xfG:|aYOgRZN{[Xl? M3XFUVAuOTByIH7N NIGxWI4zPC92ODDo MlvRbY5lfWOnczDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NWPnPXdvOjRzNkOyN|A>
PC3-AR NVG3OWp7SXCxcITvd4l{KEG|c3H5 M{jzOlAuOTByIH7N MkHZNlQwPDhiaB?= MVrpcoR2[2W|IHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NUj3flNsOjRzNkOyN|A>
PC3 NULGSlNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6yNE0yODBibl2= MoTpNlQwPDhiaB?= MUHpcoR2[2W|IHHjZ5VufWyjdHnvckBw\iC|dXLHNUBxd3C3bHH0bY9v NFH1TJUzPDF4M{KzNC=>
PC3-AR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVHpelV6OC1zMECgcm0> M2PlcFI1NzR6IHi= MlTkbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW|dDDpckB1cGViR{LNJJBp[XOn NVnNdYNiOjRzNkOyN|A>
PC3 NILQW41HfW6ldHnvckBCe3OjeR?= MnXINE0yODBibl2= NF[wN40zPCCq M3z2c5N2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu MkjVNlQyPjN{M{C=
PC3-AR MoTySpVv[3Srb36gRZN{[Xl? MkSwNE0yODBibl2= NYTXbYxXOjRiaB?= M1vU[JN2eHC{ZYPz[ZMh\XiycnXzd4lwdiCxZjDhZ5RqfmG2ZXSgRXRONCCDa4SgZY5lKEW{a{GvNkBxem:2ZXnu MmLCNlQyPjN{M{C=
OS-RC-2 MUTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml\lNE0yODByIH7N NVK1XWpSOjRxNEivO|IhcA>? M{\Ec2ROW09? NY\jOXh5\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NF3mU4QzPDF2NEezOy=>
OS-RC-2 NVfKNItvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXJTIFGPTBibl2= M1XCd|Q5KGh? MXLEUXNQ MW\pcoR2[2W|IFeyM20h[XK{ZYP0 NWLWbZU4OjRzNES3N|c>
OS-RC-2 NHLEO4FCeG:ydH;zbZMhSXO|YYm= Mo\VOVAhdk1? NX7R[nlWPDhiaB?= M363emROW09? MmjmbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? MUWyOFE1PDd|Nx?=
SK-N-AS MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\tclDjiJN6MDDuUS=> NIfLPXM1QCCq M4jGS2lEPTB;MkeuOEBvVQ>? NEDkfIYzPDB7OEe5PS=>
SK-N-DZ MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3i1NlDjiJN6MDDuUS=> NYTPTpA6PDhiaB?= MoHpTWM2OD1{MT65JI5O NGnaeoszPDB7OEe5PS=>
SK-N-SH NGnIfYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2T3[|DjiJN6MDDuUS=> M2nIUVQ5KGh? NVfPeHlnUUN3ME23Nk4{KG6P MUKyOFA6QDd7OR?=
SK-N-BE NVrKOpA2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIiySYox6oDVOECgcm0> NVHPWG1wPDhiaB?= MUXJR|UxRTd3LkSgcm0> MnniNlQxQTh5OUm=
SK-N-AS MUPBdI9xfG:|aYOgRZN{[Xl? MYSw5qCUQDBibl2= MV[0PEBp MX7wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36= MV2yOFA6QDd7OR?=
SK-N-DZ M1vze2Fxd3C2b4Ppd{BCe3OjeR?= MYqw5qCUQDBibl2= MUe0PEBp MlHvdI91\W62bImgbY5lfWOnZDDhdI9xfG:|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u MWOyOFA6QDd7OR?=
SK-N-SH MkTMRZBweHSxc3nzJGF{e2G7 NVXVRolmOOLCk{SwJI5O M1jmeVQ5KGh? NHLL[5hxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> MUeyOFA6QDd7OR?=
SK-N-BE MVrBdI9xfG:|aYOgRZN{[Xl? MYmw5qCUPDBibl2= MYq0PEBp NEHFdVBxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44> NVfVRXFjOjRyOUi3PVk>
SK-N-AS NVG5WmMxTnWwY4Tpc44hSXO|YYm= MnPPNQKBmzhyIH7N NFW5PVA1QCCq M4PaWYlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> NX[wUo1sOjRyOUi3PVk>
SK-N-DZ MUXGeY5kfGmxbjDBd5NigQ>? NXv1ZW5KOOLCk{iwJI5O NE\jSHc1QCCq M{XN[4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA> MYmyOFA6QDd7OR?=
SK-N-SH NUXTdXlDTnWwY4Tpc44hSXO|YYm= MWSw5qCUPDBibl2= MmfYOFghcA>? MmHsbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=> Mlm1NlQxQTh5OUm=
SK-N-BE M1:5V2Z2dmO2aX;uJGF{e2G7 MYiw5qCUPDBibl2= MlXKOFghcA>? MX7pcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiY3zlZZZi\2Vib3[gZ4F{eGG|ZTCzJIFv\CCSQWLQ M2q2SFI1ODl6N{m5
HCC-LM3 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWCxMVExODBibl2= NHrwOFczPC92OD:3NkBp MWXEUXNQ NEXS[WVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NHjadlgzPDB7M{m1Oi=>
HepG2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEKzO5kyNTFyMECgcm0> MmrzNlQwPDhxN{KgbC=> NEDXZW9FVVOR NF;3bGpqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MV2yOFA6Ozl3Nh?=
SMMC-7721 M3HmNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{L6R|EuOTByMDDuUS=> NETt[2MzPC92OD:3NkBp MUDEUXNQ M{\0bYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NXq2UY5pOjRyOUO5OVY>
HCC-LM3 M2PpeWFxd3C2b4Ppd{BCe3OjeR?= MWG1NEBvVQ>? NFfNWmc1QCCq M3fFS2ROW09? M3PwUYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 Ml\RNlQxQTN7NU[=
HepG2 MVvBdI9xfG:|aYOgRZN{[Xl? Mk\kOVAhdk1? M1fsbFQ5KGh? MnLYSG1UVw>? M1XGR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6 MVqyOFA6Ozl3Nh?=
SMMC-7721 M{\0d2Fxd3C2b4Ppd{BCe3OjeR?= M2DYcFUxKG6P MlrtOFghcA>? M4jQcWROW09? NWHJb4k1cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl? MXeyOFA6Ozl3Nh?=
HCC-LM3 NY\RV2pvTnWwY4Tpc44hSXO|YYm= Mne3OVAwOTByIH7N MnzPNlQhcA>? NIjZVlJFVVOR MnPZ[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?= M3nDNlI1ODl|OUW2
HepG2 M1rUSGZ2dmO2aX;uJGF{e2G7 MWm1NE8yODBibl2= MWGyOEBp NFKxTodFVVOR NUD6R3c{\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> M1i3dFI1ODl|OUW2
SMMC-7721 NV[z[lZNTnWwY4Tpc44hSXO|YYm= NEXwcWQ2OC9zMECgcm0> NGHkU|UzPCCq NXvDPZNYTE2VTx?= NUjQWGpY\GWlcnXhd4V{KHSqZTDs[ZZmdHNib3[gdE1UXEGWMzDhcoQheC2Da4VCpC=> MXyyOFA6Ozl3Nh?=
HCC-LM3 M1HsVmZ2dmO2aX;uJGF{e2G7 M3u3XFUxNzFyMDDuUS=> Mn\xNlQhcA>? MmHxSG1UVw>? MkDn[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>? NW\hWYh{OjRyOUO5OVY>
HepG2 NYG0fJp5TnWwY4Tpc44hSXO|YYm= MmDtOVAwOTByIH7N MnnoNlQhcA>? NYPhUndvTE2VTx?= NF7FU4Zld3ewcnXneYxifGW|IFLjcE15VCCneIDy[ZN{cW:w NYjSTHdpOjRyOUO5OVY>
SMMC-7721 NYHY[ppvTnWwY4Tpc44hSXO|YYm= Mnj6OVAwOTByIH7N MoTQNlQhcA>? MlnFSG1UVw>? NUjJcnA1\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?= NEPZdIkzPDB7M{m1Oi=>
FaDu MkfBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXe0bGxqOTBy4pEFcm0> NW\OZ3JRQC9zMD:xNkBp MVfkbZNxdGG7ZXSgZUB{cWewaX\pZ4FvfCCjbnSgdJJwdG:wZ3XkJGczN01iYYLy[ZN1KGG2IEigZY5lKDF{4pEFbEBxd3O2IILlcIVie2V? NX\GbpJmOjRyMk[0PFI>
FaDu M3HYSWZ2dmO2aX;uJGF{e2G7 NFPDblYyODEkgJXuUS=> M2L2WlIwPC96L{GyJIg> MXLpcoR2[2WmIICyNXdi\jFxQ3nwNeKh\XiycnXzd4lwdg>? MWeyOFAzPjR6Mh?=
PC-3  NF\0SndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LaRVAuOTBizszN NVvHWJRMOjRxNEivO|IhcA>? NH3OdW5qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MX[yN|k6OTJzNh?=
LNCaP MmTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO4ZVQxNTVizszN NGjsclYzPC92OD:3NkBp NG\CSnZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= Ml;rNlM6QTF{MU[=
RWPE-1  MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnhW|IxNTJyIN88US=> MoXoNlQwPDhxN{KgbC=> M{HMZolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXuyN|k6OTJzNh?=
Capan-1 MkTOSpVv[3Srb36gRZN{[Xl? MWqyOU82OC9zMECgcm0> MX24M|I1NzR6IHi= NGC0b3JFVVOR M17MXIRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne= M1m1Z|I{QTJ{OEi2
L3.6pl M1TjcmZ2dmO2aX;uJGF{e2G7 MorSNlUwPTBxMUCwJI5O NHn0TnI5NzJ2L{S4JIg> MWnEUXNQ MYjkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p NV7NSHZLOjN7MkK4PFY>
CFPAC-1  NVfYb49[TnWwY4Tpc44hSXO|YYm= MoXFNlUwPTBxMUCwJI5O MkSwPE8zPC92ODDo Mn7tSG1UVw>? NFqxVIpld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n M1LxdFI{QTJ{OEi2
Capan-1 NVSy[3VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGDmPZgzPS93MD:xNFAhdk1? NIfQdZM1QCCq NHfwd3JFVVOR MXfy[YR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy Mn3zNlM6OjJ6OE[=
L3.6pl M{ixcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rHeFI2NzVyL{GwNEBvVQ>? MWq0PEBp Mo\YSG1UVw>? MmnudoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NI[ye44zOzl{Mki4Oi=>
CFPAC-1  NITPVGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXzNlUwPTBxMUCwJI5O M121elQ5KGh? MYjEUXNQ NWn3cpN4emWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? M37CT|I{QTJ{OEi2
Capan-1 NGXGclBCeG:ydH;zbZMhSXO|YYm= MXeyOU82OC9zMECgcm0> Ml7XOFghcA>? MkLkSG1UVw>? M3HKW4lv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MXWyN|kzOjh6Nh?=
L3.6pl MVnBdI9xfG:|aYOgRZN{[Xl? MlzRNlUwPTBxMUCwJI5O M33CdFQ5KGh? NX\4elRvTE2VTx?= MYXpcoR2[2W|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MXuyN|kzOjh6Nh?=
CFPAC-1  M1L5NWFxd3C2b4Ppd{BCe3OjeR?= NUe1dJN{OjVxNUCvNVAxKG6P MXS0PEBp NILTPJRFVVOR NUTnZXR2cW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXPLWFVrOjN7MkK4PFY>
HN22 NH33cXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MViwMVIxKG6P MXyyOE81QCCq M1P0e2ROW09? NFfqNnJqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz MmOwNlM5Pzd{M{W=
HSC4  NYnjUXl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\XWGcxNTJyIH7N Moe5NlQwPDhiaB?= M1rjVGROW09? M{nBfolvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> M1zlTFI{QDd5MkO1
HN22 Mmr1RZBweHSxc3nzJGF{e2G7 M{[3dFAuOjBibl2= MlXBOFghcA>? NIjONmlFVVOR MWDpcoR2[2W|IHPlcIwh[XCxcITvd4l{ NUPMcZlSOjN6N{eyN|U>
HSC4  NHn5[mtCeG:ydH;zbZMhSXO|YYm= NV\QbJliOC1{MDDuUS=> NHP4NZA1QCCq M{fvOWROW09? M4LpWYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? M3rTWVI{QDd5MkO1
HN22 M1XnfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYqwMVIxKG6P NUL3SJlTPDhiaB?= MV\EUXNQ M1zDOYlv\HWlZYOgS|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=> M{[3VFI{QDd5MkO1
HSC4  NWn2copNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILFeHgxNTJyIH7N NEO5O5E1QCCq NFXJ[I5FVVOR NVPqenZkcW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh MV6yN|g4PzJ|NR?=
HN22 M3nX[WZ2dmO2aX;uJGF{e2G7 M2HVRVAuOjBibl2= NEDKRY01QCCq MX;EUXNQ M3izTpN2eHC{ZYPz[ZMhW3BzIHX4dJJme3Orb39CpC=> MWiyN|g4PzJ|NR?=
HSC4  MVzGeY5kfGmxbjDBd5NigQ>? NHfSSHYxNTJyIH7N NHnGUZY1QCCq M3yzOGROW09? MYfzeZBxemW|c3XzJHNxOSCneIDy[ZN{cW:wwrC= NF32UXMzOzh5N{KzOS=>
Cal62 NVfLUZlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ezUWlEPTB;M{OgxtEhPCCwTR?= MWSyN|gzPDB4NB?=
Hth7 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfITWM2OD1zNTFCtUAzKG6P MmLQNlM5OjRyNkS=
Hth83 NGC5bnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVj2cGFiUUN3ME2zOEDDuSB3IH7N NX\aS5gxOjN6MkSwOlQ>
C643 NUW0Z4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHX3SoRKSzVyPUexJOKyKDFyIH7N M4njflI{QDJ2ME[0
SW1736 NE\1VIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfObndOUUN3ME2zOUDDuSB6IH7N NIixc2MzOzh{NEC2OC=>
T241 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPTTWM2OD14NTFCtUA4KG6P M1\MXFI{QDJ2ME[0
T351 Mn\DS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVfXZmRCUUN3ME21NEDDuSBzMDDuUS=> NFjRdHQzOzh{NEC2OC=>
BHP2-7 NUT3SpB3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLtTWM2OD1|NzFCtUA3KG6P NXrpboN7OjN6MkSwOlQ>
T238 NFH2[YlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjM[5hKSzVyPUGsOVAxKMLzIEKwNEBvVQ>? M4j3ZlI{QDJ2ME[0
HCT8 NIL3SW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnVdGE3PzJiaB?= NVLXfGpvTE2VTx?= NV;oSIM2UUN3ME2xNk466oDLwsJihKkyNjlibl2= M4S2dlI{Ojl7M{i4
H630 MkLZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDrbY84OiCq NVrMfGJKTE2VTx?= MV;JR|UxRTF{LkVihKnDueLCiUOuNUBvVQ>? NVHkPWhnOjN{OUmzPFg>
cH630 5-FU-res NH3acWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\Rc5k4OiCq M4W0PGROW09? MYTJR|UxRTF3LkZihKnDueLCiUGuNkBvVQ>? NV;L[2txOjN{OUmzPFg>
HCT116 MnLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\5doo4OiCq NHLkdWVFVVOR NVOwVmtjUUN3ME2xNE446oDLwsJihKkzNjJibl2= MV:yN|I6QTN6OB?=
HCT116 p53−/− MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvXO|IhcA>? MkLLSG1UVw>? M1vuRWlEPTB;OD625qCKyrIkgJmxMlchdk1? M2fQe|I{Ojl7M{i4
dHCT116 p21−/− NF7OeJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnTO|IhcA>? NUH0ZmdLTE2VTx?= MnOxTWM2OD13LkpihKnDueLCiUGuN{BvVQ>? M3LBOlI{Ojl7M{i4
HT29 MlTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWi2UlJvPzJiaB?= MWLEUXNQ MoPPTWM2OD1zNj6z5qCKyrIkgJmyMlMhdk1? MoLkNlMzQTl|OEi=
LoVo MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk\xO|IhcA>? MVfEUXNQ Ml7nTWM2OD13LkJihKnDueLCiUCuOkBvVQ>? Mn;QNlMzQTl|OEi=
RKO NWLrWo92T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3mcVFSPzJiaB?= NGHQelRFVVOR M4fMeGlEPTB;Nz655qCKyrIkgJmyMlIhdk1? M3HhRVI{Ojl7M{i4
SW480 NUHNPHFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVm3NkBp MXnEUXNQ MnnxTWM2OD1zNz615qCKyrIkgJmwMlghdk1? MoTBNlMzQTl|OEi=
eSW620 NXr0PWRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYK3NkBp M{nyc2ROW09? NGPlb2NKSzVyPUmuNgKBkcLz4pEJNk4yKG6P NEXYPVAzOzJ7OUO4PC=>

... Click to View More Cell Line Experimental Data

In vivo In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. [2]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
  • Concentrations: 50 nM
  • Incubation Time: 48 hours
  • Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 104 cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (107 cells) or A549 (5 × 106 cells), H69 (2.5 × 106 cells), BK-T (6.5 × 106), H526 (10 × 106), and RG1 (10 × 106) cells
  • Formulation: Dextrose 5% in water
  • Dosages: 10 mg/kg, 20 mg/kg
  • Administration: Administered via i.p. injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+48% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 349.43
Formula

C21H23N3O2

CAS No. 404950-80-7
Storage powder
in solvent
Synonyms NVP-LBH589

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03632317 Recruiting Glioma|Diffuse Intrinsic Pontine Glioma University of Michigan Rogel Cancer Center March 2019 Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2
NCT03566199 Recruiting Diffuse Intrinsic Pontine Glioma Sabine Mueller MD PhD|Midatech Pharma US Inc.|Pacific Pediatric Neuro-Oncology Consortium|University of California San Francisco May 22 2018 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    How to reconstitute the compound for in vivo mice study?

  • Answer:

    We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Panobinostat (LBH589) | Panobinostat (LBH589) supplier | purchase Panobinostat (LBH589) | Panobinostat (LBH589) cost | Panobinostat (LBH589) manufacturer | order Panobinostat (LBH589) | Panobinostat (LBH589) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID